# Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

> **NCT00881166** · PHASE1 · COMPLETED · sponsor: **Astex Pharmaceuticals, Inc.** · enrollment: 101 (actual)

## Conditions studied

- Malignant Disease

## Interventions

- **DRUG:** MP-470 + topotecan
- **DRUG:** MP-470 + docetaxel
- **DRUG:** MP-470 + erlotinib
- **DRUG:** MP-470 + paclitaxel/carboplatin
- **DRUG:** MP-470 + carboplatin/etoposide

## Key facts

- **NCT ID:** NCT00881166
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2024-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00881166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00881166, "Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00881166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*